July 2026's Top Stocks Believed To Be Trading Below Intrinsic Value
Simply Wall St lists US stocks it says trade below intrinsic value, citing cash-flow discounts. It highlights AbbVie (market cap ~$453.9B, 43.4% discount), Guidewire ( ~$12.4B, 23.7% discount, FY2026 guidance revenue ~$1.46-$1.47B), and Unity ( ~$13.3B, 46.7% discount).
How this was made
The 30-second read
Why it matters
The only potentially decision-relevant items are the explicit FY2026 guidance ranges for Guidewire and the mention of a European RINVOQ approval for AbbVie. The rest is largely valuation framing with forecasts and general risk notes.
Market read
Traders may use the guidance numbers for GWRE as a re-rating input, but the article is primarily a promotional valuation list without new, time-critical catalysts.
What to watch
The piece does not quantify how sensitive the fair-value estimates are to discount rates, cash-flow assumptions, or competitive/product risks; it also lacks confirmation of whether the cited guidance/product events are already fully priced.
Background
Simply Wall St presents a screen of US stocks it believes trade below intrinsic value, using cash-flow-based fair value estimates and analyst forecasts.
Ticker impact
Article claims AbbVie is trading 43.4% below estimated future cash-flow fair value and cites European RINVOQ approval as a potential revenue bolster.
Mild, sentiment-driven support rather than a discrete repricing catalyst.
The text provides a discount-to-fair-value estimate and mentions a European approval, but it does not include new financial guidance, trial results, or a dated regulatory decision beyond the approval reference.
Article says Guidewire is trading 23.7% below fair value and reports it raised fiscal 2026 earnings guidance with revenue and operating income ranges.
Potential near-term positive drift as traders reprice FY26 expectations.
The article includes concrete guidance numbers (revenue range and operating income ceiling) tied to third-quarter strength, which can drive positioning even if it is not a full earnings release.
Article states Unity is trading 46.7% below fair value and highlights a Q1 2026 net loss plus a forecast for rapid earnings growth and profitability within three years.
Choppy reaction risk; valuation support may be tempered by continued profitability concerns.
The article provides forecasts and loss figures but no new operational milestone, guidance update, or dated event beyond the general Q1 loss reference.
Market effects
Biopharma and software names are framed as undervalued, but the article does not provide sector-wide new data.
Mentions US market performance and a European approval for one drug, but no broader regional shock.
Limited to company-specific valuation and one product-approval reference; no global macro or cross-border deal details.
Counterpoint
Discount-to-fair-value screens can reflect real risks (debt coverage, profitability timelines, or model assumptions), so the 'undervalued' label may not translate into near-term returns.
Key entities
- companyAbbVie Inc.
Biopharmaceutical company; article cites a 43.4% cash-flow fair value discount and a European RINVOQ approval as a revenue support factor.
- companyGuidewire Software, Inc.
P&C insurance software provider; article claims a 23.7% fair value discount and reports raised FY2026 guidance with revenue and operating income ranges.
- companyUnity Software Inc.
Game/interactive platform; article cites a 46.7% fair value discount and a Q1 2026 net loss alongside rapid earnings growth forecasts.
